Paratek Pharmaceuticals, Inc. (PRTK) — Financial statements
Income statement, balance sheet, and cash flow for Paratek Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 151↑24.7% | 121↑177.9% | 44↑163.0% | 17↓3.3% | 17 | |
| Cost of Revenue | 23↑7.1% | 22↑148.9% | 9↑148.3% | 3 | 0.00 | |
| Gross Profit | 128↑28.5% | 99↑185.1% | 35↑167.0% | 13↓23.7% | 17 | |
| Operating Expenses | ||||||
| R&D Expenses | 38↑24.6% | 30↑26.9% | 24↓39.5% | 40↓31.2% | 58 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 64 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 146↑21.9% | 119↑32.9% | 90↑0.8% | 89↑40.0% | 64 | |
| Other Expenses | -9↓2.9% | -9↓170.4% | -3↓10890.3% | -0.03↑29.5% | -0.04 | |
| Operating Expenses | 174↑23.8% | 141↑27.3% | 110↓14.2% | 129↑6.2% | 121 | |
| Total Costs & Expenses | 197↑21.5% | 162↑36.2% | 119↓10.0% | 132↑9.1% | 121 | |
| Operating Results | ||||||
| Operating Income | -46↓12.3% | -41↑45.5% | -76↑34.7% | -116↓11.1% | -104 | |
| Depreciation & Amortization | 1↑194.2% | 0.45↓71.7% | 2↓55.7% | 4↑432.1% | -1 | |
| EBITDA | -45↓10.4% | -41↑45.0% | -74↑31.9% | -109↓7.6% | -101 | |
| EBIT | -45↓10.5% | -41↑46.2% | -76↑31.9% | -112↓11.1% | -101 | |
| Interest & Other Income | ||||||
| Net Interest Income | -17↓0.1% | -17↑7.4% | -19↓46.0% | -13↓66.1% | -8 | |
| Interest Income | 0.75↑1039.4% | 0.07↓95.6% | 2↓57.6% | 4↑9.6% | 3 | |
| Interest Expense | 18↑4.1% | 17↓14.0% | 20↑23.4% | 16↑49.3% | 11 | |
| Non-Operating Income | -0.82↓1416.7% | -0.05↓106.8% | 0.80↑122.5% | -4↓10.2% | -3 | |
| Other Income / Expenses | -17↑0.3% | -17↑17.5% | -21↓63.6% | -13↓65.5% | -8 | |
| Income Before Tax | -64↓8.6% | -58↑39.4% | -97↑24.9% | -128↓14.9% | -112 | |
| Income Tax Expense | 0.06↓90.5% | 0.60↓97.0% | 20↑6450.8% | 0.30↓40.0% | 0.50 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -64↓7.6% | -59↑49.2% | -116↑9.7% | -129↓14.6% | -112 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -64↓7.6% | -59↑49.2% | -116↑9.7% | -129↓14.6% | -112 | |
| Bottom-Line Net Income | -64↓7.6% | -59↑49.2% | -116↑9.7% | -129↓14.6% | -112 | |
| EPS (Basic) | -1.17↑4.1% | -1.22↑53.6% | -2.63↑33.1% | -3.93↓10.1% | -3.57 | |
| EPS (Diluted) | -1.17↑4.1% | -1.22↑53.6% | -2.63↑33.1% | -3.93↓10.1% | -3.57 | |
| Weighted Average Shares | 54↑12.3% | 48↑9.6% | 44↑34.7% | 33↑4.1% | 32 | |
| Weighted Average Diluted Shares | 54↑12.3% | 48↑9.6% | 44↑34.7% | 33↑4.1% | 32 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.